SG10201609131YA - Zinc-pga compositions and methods for treating cancer - Google Patents
Zinc-pga compositions and methods for treating cancerInfo
- Publication number
- SG10201609131YA SG10201609131YA SG10201609131YA SG10201609131YA SG10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- tumors
- compositions
- zinc
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical class [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920002643 polyglutamic acid Polymers 0.000 abstract 2
- 206010061968 Gastric neoplasm Diseases 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 abstract 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 1
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000684 flow cytometry Methods 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000037841 lung tumor Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000955 neuroendocrine Effects 0.000 abstract 1
- 208000025421 tumor of uterus Diseases 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
ZINC-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER The invention relates to pharmaceutical compositions comprising a zinc 2+ salt and a g -polyglutamic acid carrier, and, optionally, an NF-kB inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. An in vitro flow cytometric analysis of human cancer lines treated with one embodiment of a ZnPGA composition, Figure 2, demonstrate that the methods of the invention induce PARP1-mediated tumor necrosis, the method comprising administering a therapeutically effective amount of a Zn(II) salt and a g -polyglutamic acid carrier to the tumor. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, using the disclosed compositions are provided. Tumors that respond to the pharmaceutical compositions disclosed herein include neuroendocrine (neuroblastoma), gastric, uterine, and lung tumors. Figure 2
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201609131YA SG10201609131YA (en) | 2016-11-01 | 2016-11-01 | Zinc-pga compositions and methods for treating cancer |
EP17798014.1A EP3534914A1 (en) | 2016-11-01 | 2017-10-31 | Zinc- -pga compositions and methods for treating cancer |
KR1020197015744A KR102616690B1 (en) | 2016-11-01 | 2017-10-31 | Zinc-γ-PGA compositions and methods for treating cancer |
JP2019545869A JP7083835B2 (en) | 2016-11-01 | 2017-10-31 | Zinc-γ-PGA composition and methods for treating cancer |
AU2017354787A AU2017354787B2 (en) | 2016-11-01 | 2017-10-31 | Zinc-gamma-PGA compositions and methods for treating cancer |
US16/346,286 US11944640B2 (en) | 2016-11-01 | 2017-10-31 | Zinc-[gamma]-PGA compositions and methods for treating cancer |
CA3042383A CA3042383A1 (en) | 2016-11-01 | 2017-10-31 | Zinc-.gamma.-pga compositions and methods for treating cancer |
SG11201903753QA SG11201903753QA (en) | 2016-11-01 | 2017-10-31 | Zinc-?-pga compositions and methods for treating cancer |
SG10202013112YA SG10202013112YA (en) | 2016-11-01 | 2017-10-31 | Zinc-gamma-pga compositions and methods for treating cancer |
MX2019005104A MX2019005104A (en) | 2016-11-01 | 2017-10-31 | Zinc-y-pga compositions and methods for treating cancer. |
PCT/SG2017/050545 WO2018084806A1 (en) | 2016-11-01 | 2017-10-31 | ZINC-γ-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER |
CN202310311382.9A CN116350658A (en) | 2016-11-01 | 2017-11-01 | Zinc-gamma-PGA compositions and methods of treating cancer |
CN201711108631.5A CN108014131B (en) | 2016-11-01 | 2017-11-01 | Zinc-gamma-PGA compositions and methods for treating cancer |
MX2022011372A MX2022011372A (en) | 2016-11-01 | 2019-04-30 | Zinc-î³-pga compositions and methods for treating cancer. |
JP2022089345A JP7466822B2 (en) | 2016-11-01 | 2022-06-01 | Zinc-γ-PGA Compositions and Methods for Treating Cancer - Patent application |
AU2023203220A AU2023203220A1 (en) | 2016-11-01 | 2023-05-23 | Zinc-gamma-pga compositions and methods for treating cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201609131YA SG10201609131YA (en) | 2016-11-01 | 2016-11-01 | Zinc-pga compositions and methods for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201609131YA true SG10201609131YA (en) | 2018-06-28 |
Family
ID=60327362
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201609131YA SG10201609131YA (en) | 2016-11-01 | 2016-11-01 | Zinc-pga compositions and methods for treating cancer |
SG11201903753QA SG11201903753QA (en) | 2016-11-01 | 2017-10-31 | Zinc-?-pga compositions and methods for treating cancer |
SG10202013112YA SG10202013112YA (en) | 2016-11-01 | 2017-10-31 | Zinc-gamma-pga compositions and methods for treating cancer |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903753QA SG11201903753QA (en) | 2016-11-01 | 2017-10-31 | Zinc-?-pga compositions and methods for treating cancer |
SG10202013112YA SG10202013112YA (en) | 2016-11-01 | 2017-10-31 | Zinc-gamma-pga compositions and methods for treating cancer |
Country Status (10)
Country | Link |
---|---|
US (1) | US11944640B2 (en) |
EP (1) | EP3534914A1 (en) |
JP (2) | JP7083835B2 (en) |
KR (1) | KR102616690B1 (en) |
CN (2) | CN108014131B (en) |
AU (2) | AU2017354787B2 (en) |
CA (1) | CA3042383A1 (en) |
MX (2) | MX2019005104A (en) |
SG (3) | SG10201609131YA (en) |
WO (1) | WO2018084806A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022197246A1 (en) | 2021-03-18 | 2022-09-22 | Xylonix Pte. Ltd | Pharmaceutical polymer conjugates |
US11944640B2 (en) | 2016-11-01 | 2024-04-02 | Xylonix PTE. LTD. | Zinc-[gamma]-PGA compositions and methods for treating cancer |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201708886RA (en) * | 2017-10-30 | 2019-05-30 | Xylonix Ip Holdings Pte Ltd | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
JP2021527707A (en) * | 2018-06-22 | 2021-10-14 | ジロニックス・アイピー・ホールディングス・ピーティーイー.リミテッド | Oncological treatment with zinc |
KR102094182B1 (en) * | 2018-06-28 | 2020-03-30 | 주식회사 알랙스탠드 | water-soluble polyglutamic acid complex composition containing zinc |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2897122A (en) | 1956-10-04 | 1959-07-28 | Frosst & Co Charles E | Enteric coated product |
JP2712583B2 (en) | 1989-06-28 | 1998-02-16 | 味の素株式会社 | Foods and drinks containing easily absorbable minerals |
JP3551149B2 (en) | 1992-03-24 | 2004-08-04 | 味の素株式会社 | Easy-absorbable mineral-containing composition and food and drink containing it |
EP0605757B1 (en) | 1992-11-25 | 2001-08-16 | Ajinomoto Co., Inc. | Compositions and goods containing minerals and poly-gamma-glutamic acid |
US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
ITMI950515A0 (en) | 1995-03-16 | 1995-03-16 | Valpharma Sa | GASTRO-RESISTANT FORMULATIONS CONTAINING ZINC |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
JPH11313618A (en) | 1998-05-06 | 1999-11-16 | Yoshio Inoue | Mineral (zinc) formulation for livestock gentle to stomach and its production |
US6462075B1 (en) | 1999-12-23 | 2002-10-08 | The University Of Georgia Research Foundation, Inc. | Chalcone and its analogs as agents for the inhibition of angiogensis and related disease states |
US20020061599A1 (en) | 1999-12-30 | 2002-05-23 | Elling Christian E. | Method of identifying ligands of biological target molecules |
US8168657B2 (en) | 2002-01-25 | 2012-05-01 | Bowen J Phillip | Solenopsin A, B and analogs and as novel angiogenesis inhibitors |
WO2004080210A1 (en) | 2003-03-14 | 2004-09-23 | Boehringer Ingelheim Danmark A/S | Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea |
KR100498812B1 (en) | 2003-07-10 | 2005-07-01 | 주식회사 바이오리더스 | Composition for promoting an absorption of mineral in body comprising poly-gamma-glutamic acid having ultla high molecular weight |
JP4457641B2 (en) | 2003-11-10 | 2010-04-28 | 味の素株式会社 | Gelatin capsule |
JP5162812B2 (en) | 2004-07-08 | 2013-03-13 | 大正製薬株式会社 | Zinc-containing composition for oral administration |
EP1890537B1 (en) | 2005-06-07 | 2012-08-08 | Yale University | Methods of treating cancer and other conditions or disease states using lfmau and ldt |
CA2612979A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | Parp modulators and treatment of cancer |
WO2007043606A1 (en) * | 2005-10-12 | 2007-04-19 | Genolac Bl Corporation | Antidiabetic agent comprising anionic polyamino acid-metal complex |
US7528125B2 (en) | 2006-03-20 | 2009-05-05 | Jonathan L. Sessler | Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer |
CN101674852A (en) | 2007-04-10 | 2010-03-17 | 日东电工株式会社 | Multi-functional polyglutamate drug carriers |
BRPI0811557A2 (en) | 2007-05-09 | 2019-09-24 | Salutria Pharmaceuticals Llc | compound, pharmaceutical composition, method of treatment or prophylaxis of an inflammatory condition. |
EP2155253A2 (en) | 2007-05-09 | 2010-02-24 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
EP2416786A1 (en) | 2009-04-10 | 2012-02-15 | Cypress Pharmaceutical, Inc. | Phosphate-binding magnesium salts and uses thereof |
JO3635B1 (en) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | Solid pharmaceutical compositions and processes for their production |
CN101716180B (en) | 2009-11-06 | 2013-04-24 | 广西强寿药业集团有限公司 | Combined medicament for supplementing zinc and calcium and preparation method thereof |
US20110117210A1 (en) | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
EP2544660B1 (en) | 2010-03-10 | 2018-06-13 | Lupin Limited | Rifaximin ready-to-use suspension |
SG2014014419A (en) | 2011-09-13 | 2014-07-30 | Pharmacyclics Inc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
BR112015011699B1 (en) | 2012-11-21 | 2021-01-12 | KBS Research, LLC | herbal supplements and their uses |
TWI660748B (en) | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | Suspension for oral administration comprising amorphous tolvaptan |
US9132098B2 (en) | 2013-03-28 | 2015-09-15 | Bbs Nanotechnology Ltd. | Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it |
CN105120876A (en) | 2013-04-12 | 2015-12-02 | R·L·本特 | Cancer therapy |
WO2014175898A1 (en) | 2013-04-26 | 2014-10-30 | Nitto Denko Corporation | A large scale process for preparing poly (glutamyl-glutamate) conjugates |
WO2015009699A1 (en) | 2013-07-15 | 2015-01-22 | Ketter Patrick | Methods and compositions to prevent or treat bacterial infections |
JP2016069303A (en) | 2014-09-29 | 2016-05-09 | タカラバイオ株式会社 | Hair loss inhibiting composition containing fucoidan as active ingredient |
ES2630106T3 (en) | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
KR102467968B1 (en) | 2014-10-08 | 2022-11-16 | 신세틱 바이오로직스, 인코퍼레이티드 | Beta-lactamase formulations and uses thereof |
US20160122739A1 (en) | 2014-10-31 | 2016-05-05 | Wisconsin Alumni Research Foundation | Factor ix variants and methods of use therefor |
WO2016088816A1 (en) | 2014-12-03 | 2016-06-09 | ノーベルファーマ株式会社 | Tablet comprising zinc acetate hydrate and method for manufacturing same |
CN109890405A (en) | 2016-08-19 | 2019-06-14 | 布鲁克林免疫治疗有限公司 | PD-1/PD-L1 inhibitor and/or CTLA-4 inhibitor and the biological agent containing cytokine profiles component are used for the purposes for the treatment of cancer |
SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
SG10201708886RA (en) | 2017-10-30 | 2019-05-30 | Xylonix Ip Holdings Pte Ltd | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
JP2021527707A (en) | 2018-06-22 | 2021-10-14 | ジロニックス・アイピー・ホールディングス・ピーティーイー.リミテッド | Oncological treatment with zinc |
-
2016
- 2016-11-01 SG SG10201609131YA patent/SG10201609131YA/en unknown
-
2017
- 2017-10-31 US US16/346,286 patent/US11944640B2/en active Active
- 2017-10-31 AU AU2017354787A patent/AU2017354787B2/en active Active
- 2017-10-31 EP EP17798014.1A patent/EP3534914A1/en active Pending
- 2017-10-31 SG SG11201903753QA patent/SG11201903753QA/en unknown
- 2017-10-31 MX MX2019005104A patent/MX2019005104A/en unknown
- 2017-10-31 SG SG10202013112YA patent/SG10202013112YA/en unknown
- 2017-10-31 JP JP2019545869A patent/JP7083835B2/en active Active
- 2017-10-31 WO PCT/SG2017/050545 patent/WO2018084806A1/en unknown
- 2017-10-31 CA CA3042383A patent/CA3042383A1/en active Pending
- 2017-10-31 KR KR1020197015744A patent/KR102616690B1/en active IP Right Grant
- 2017-11-01 CN CN201711108631.5A patent/CN108014131B/en active Active
- 2017-11-01 CN CN202310311382.9A patent/CN116350658A/en active Pending
-
2019
- 2019-04-30 MX MX2022011372A patent/MX2022011372A/en unknown
-
2022
- 2022-06-01 JP JP2022089345A patent/JP7466822B2/en active Active
-
2023
- 2023-05-23 AU AU2023203220A patent/AU2023203220A1/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11944640B2 (en) | 2016-11-01 | 2024-04-02 | Xylonix PTE. LTD. | Zinc-[gamma]-PGA compositions and methods for treating cancer |
WO2022197246A1 (en) | 2021-03-18 | 2022-09-22 | Xylonix Pte. Ltd | Pharmaceutical polymer conjugates |
Also Published As
Publication number | Publication date |
---|---|
SG10202013112YA (en) | 2021-02-25 |
SG11201903753QA (en) | 2019-05-30 |
JP2022116255A (en) | 2022-08-09 |
JP7083835B2 (en) | 2022-06-13 |
US11944640B2 (en) | 2024-04-02 |
CN108014131A (en) | 2018-05-11 |
US20190255104A1 (en) | 2019-08-22 |
JP2019534330A (en) | 2019-11-28 |
MX2022011372A (en) | 2022-10-10 |
KR102616690B1 (en) | 2023-12-21 |
WO2018084806A1 (en) | 2018-05-11 |
AU2017354787A1 (en) | 2019-05-16 |
AU2023203220A1 (en) | 2023-06-22 |
AU2017354787B2 (en) | 2023-02-23 |
JP7466822B2 (en) | 2024-04-15 |
EP3534914A1 (en) | 2019-09-11 |
MX2019005104A (en) | 2019-10-30 |
CN108014131B (en) | 2023-04-14 |
CA3042383A1 (en) | 2018-05-11 |
KR20190120159A (en) | 2019-10-23 |
CN116350658A (en) | 2023-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201609131YA (en) | Zinc-pga compositions and methods for treating cancer | |
MX2021013830A (en) | Ezh2 inhibitors for treating lymphoma. | |
WO2017079746A3 (en) | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer | |
MX2016008201A (en) | Cancer treatment using combinations of erk and raf inhibitors. | |
MX2016007351A (en) | Combination therapy for treating cancer. | |
NZ738929A (en) | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy | |
MX2019010601A (en) | Combination therapy for treating cancer. | |
MX2018003331A (en) | Administration of deuterated cftr potentiators. | |
MX2019013701A (en) | Methods of enhancing drug delivery and effectiveness of therapeutic agents. | |
MX2020008258A (en) | Pediatric niraparib formulations and pediatric treatment methods. | |
MY162903A (en) | Methods of treatment of pancreatic cancer | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
MX2018007823A (en) | Bromodomain and extra-terminal protein inhibitor combination therapy. | |
WO2016133903A3 (en) | Combination therapy for cancer treatment | |
SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
PH12020552274A1 (en) | Formulations of an axl/mer inhibitor | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
MX2022014792A (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same. | |
MX2017000886A (en) | Treating androgen deprivation therapy induced hot flashes and bone loss using cis-clomiphene. | |
MX2021007330A (en) | Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor. | |
SG10201708886RA (en) | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER | |
PH12020500666A1 (en) | Pladienolide compounds and their use | |
MX2017013666A (en) | Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer. | |
MX2020013805A (en) | Pyridopyrimidinone derivatives for use as axl inhibitors. |